APA (7th ed.) Citation

Pittman, P. R., Norris, S. L., Brown, E. S., Ranadive, M. V., Schibly, B. A., Bettinger, G. E., . . . Peters, C. J. (2016). Rift Valley fever MP-12 vaccine Phase 2 clinical trial: Safety, immunogenicity, and genetic characterization of virus isolates. Vaccine, 34(4), 523. https://doi.org/10.1016/j.vaccine.2015.11.078

Chicago Style (17th ed.) Citation

Pittman, Phillip R., et al. "Rift Valley Fever MP-12 Vaccine Phase 2 Clinical Trial: Safety, Immunogenicity, and Genetic Characterization of Virus Isolates." Vaccine 34, no. 4 (2016): 523. https://doi.org/10.1016/j.vaccine.2015.11.078.

MLA (9th ed.) Citation

Pittman, Phillip R., et al. "Rift Valley Fever MP-12 Vaccine Phase 2 Clinical Trial: Safety, Immunogenicity, and Genetic Characterization of Virus Isolates." Vaccine, vol. 34, no. 4, 2016, p. 523, https://doi.org/10.1016/j.vaccine.2015.11.078.